1
|
Gómez-Escobedo R, Méndez-Álvarez D, Vázquez C, Saavedra E, Vázquez K, Alcántara-Farfán V, Cordero-Martínez J, Gonzalez-Gonzalez A, Rivera G, Nogueda-Torres B. Molecular Docking-Based Virtual Screening of FDA-Approved Drugs Using Trypanothione Reductase Identified New Trypanocidal Agents. Molecules 2024; 29:3796. [PMID: 39202874 PMCID: PMC11357579 DOI: 10.3390/molecules29163796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2024] [Revised: 08/05/2024] [Accepted: 08/07/2024] [Indexed: 09/03/2024] Open
Abstract
American trypanosomiasis or Chagas disease, caused by Trypanosoma cruzi (T. cruzi), affects approximately 6-7 million people worldwide. However, its pharmacological treatment causes several uncomfortable side effects, causing patients' treatment abandonment. Therefore, there is a need for new and better treatments. In this work, the molecular docking of nine hundred twenty-four FDA-approved drugs on three different sites of trypanothione reductase of T. cruzi (TcTR) was carried out to find potential trypanocidal agents. Finally, biological evaluations in vitro and in vivo were conducted with the selected FDA-approved drugs. Digoxin, alendronate, flucytosine, and dihydroergotamine showed better trypanocidal activity than the reference drugs benznidazole and nifurtimox in the in vitro evaluation against the trypomastigotes form. Further, these FDA-approved drugs were able to reduce 20-50% parasitemia in a short time in an in vivo model, although with less efficiency than benznidazole. Therefore, the results suggest a combined therapy of repurposed and canonical drugs against T. cruzi infection.
Collapse
Affiliation(s)
- Rogelio Gómez-Escobedo
- Departamento de Parasitología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico;
| | - Domingo Méndez-Álvarez
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico; (D.M.-Á.); (A.G.-G.)
| | - Citlali Vázquez
- Departamento de Bioquímica, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico; (C.V.); (E.S.)
| | - Emma Saavedra
- Departamento de Bioquímica, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico; (C.V.); (E.S.)
| | - Karina Vázquez
- Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma de Nuevo León, General Escobedo 66050, Mexico;
| | - Verónica Alcántara-Farfán
- Laboratorio de Bioquímica Farmacológica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico; (V.A.-F.); (J.C.-M.)
| | - Joaquín Cordero-Martínez
- Laboratorio de Bioquímica Farmacológica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico; (V.A.-F.); (J.C.-M.)
| | - Alonzo Gonzalez-Gonzalez
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico; (D.M.-Á.); (A.G.-G.)
| | - Gildardo Rivera
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico; (D.M.-Á.); (A.G.-G.)
| | - Benjamín Nogueda-Torres
- Departamento de Parasitología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico;
| |
Collapse
|
2
|
Sánchez Alberti A, Beer MF, Cerny N, Bivona AE, Fabian L, Morales C, Moglioni A, Malchiodi EL, Donadel OJ, Sülsen VP. In Vitro, In Vivo, and In Silico Studies of Cumanin Diacetate as a Potential Drug against Trypanosoma cruzi Infection. ACS OMEGA 2022; 7:968-978. [PMID: 35036760 PMCID: PMC8757452 DOI: 10.1021/acsomega.1c05560] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Accepted: 12/06/2021] [Indexed: 05/07/2023]
Abstract
The sesquiterpene lactones cumanin, helenalin, and hymenin and their semisynthetic derivatives were evaluated against Trypanosoma cruzi epimastigotes. The cytotoxicity of the compounds was evaluated on murine splenocytes. Cumanin diacetate was one of the most active and selective compounds [IC50 = 3.20 ± 0.52 μg/mL, selectivity index (SI) = 26.0]. This sesquiterpene lactone was selected for its evaluation on trypomastigote and amastigote forms of the parasite. The diacetylated derivative of cumanin showed moderate activity on trypomastigotes (IC50 = 32.4 ± 5.8 μg/mL). However, this compound was able to efficiently inhibit parasite replication with an IC50 value of 2.2 ± 0.05 μg/mL against the amastigote forms. Cumanin diacetate showed selectivity against the intracellular forms of Trypanosoma cruzi with an SI value of 52.7. This cumanin analogue was also active on an in vivo model of Chagas disease, leading to a reduction in the parasitemia levels in comparison with nontreated animals. Histopathological analysis of skeletal muscular tissues from treated mice showed only focal interstitial lymphocyte inflammatory infiltrates with slight myocyte necrosis; in contrast, nontreated animals showed severe lymphocyte inflammatory infiltrates with necrosis of the myocytes. A molecular docking study of cumanin and its derivatives on trypanothione reductase from T. cruzi (TcTR) was performed. The results of ΔG docking achieved let the identification of diacetylated and O-alkylated derivatives of cumanin as good inhibitors of TcTR. Cumanin diacetate could be considered a potential candidate for further studies for the development of new therapies against Chagas disease.
Collapse
Affiliation(s)
- Andrés Sánchez Alberti
- Instituto
de Microbiología y Parasitología Médica (IMPaM), CONICET—Universidad de Buenos Aires, Paraguay 2155. Piso 13, 1121 Buenos Aires, Argentina
- Cátedra
de Inmunología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956 4°P, 1113 Buenos Aires, Argentina
| | - María F. Beer
- Facultad
de Química, Bioquímica y Farmacia, Instituto de Investigaciones
en Tecnología Química (INTEQUI-CONICET), Universidad Nacional de San Luis, Área de Química
Orgánica, Almirante
Brown 1445, CP D5700HGC San Luis, Argentina
- Instituto
de Química y Metabolismo del Fármaco (IQUIMEFA), CONICET—Universidad de Buenos Aires, Junín 956 2°P, 1113 Buenos Aires, Argentina
| | - Natacha Cerny
- Instituto
de Microbiología y Parasitología Médica (IMPaM), CONICET—Universidad de Buenos Aires, Paraguay 2155. Piso 13, 1121 Buenos Aires, Argentina
- Instituto
de Estudios de la Inmunidad Humoral (IDEHU), CONICET—Universidad de Buenos Aires, Junín 956 4°P, 1113 Buenos Aires, Argentina
| | - Augusto E. Bivona
- Cátedra
de Inmunología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956 4°P, 1113 Buenos Aires, Argentina
- Instituto
de Estudios de la Inmunidad Humoral (IDEHU), CONICET—Universidad de Buenos Aires, Junín 956 4°P, 1113 Buenos Aires, Argentina
| | - Lucas Fabian
- Instituto
de Química y Metabolismo del Fármaco (IQUIMEFA), CONICET—Universidad de Buenos Aires, Junín 956 2°P, 1113 Buenos Aires, Argentina
| | - Celina Morales
- Facultad
de Medicina, Departamento de Patología, Instituto de Fisiopatología
Cardiovascular, Universidad de Buenos Aires, Buenos Aires 1113, Argentina
| | - Albertina Moglioni
- Instituto
de Química y Metabolismo del Fármaco (IQUIMEFA), CONICET—Universidad de Buenos Aires, Junín 956 2°P, 1113 Buenos Aires, Argentina
| | - Emilio L. Malchiodi
- Instituto
de Microbiología y Parasitología Médica (IMPaM), CONICET—Universidad de Buenos Aires, Paraguay 2155. Piso 13, 1121 Buenos Aires, Argentina
- Cátedra
de Inmunología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956 4°P, 1113 Buenos Aires, Argentina
- Instituto
de Estudios de la Inmunidad Humoral (IDEHU), CONICET—Universidad de Buenos Aires, Junín 956 4°P, 1113 Buenos Aires, Argentina
| | - Osvaldo J. Donadel
- Facultad
de Química, Bioquímica y Farmacia, Instituto de Investigaciones
en Tecnología Química (INTEQUI-CONICET), Universidad Nacional de San Luis, Área de Química
Orgánica, Almirante
Brown 1445, CP D5700HGC San Luis, Argentina
| | - Valeria P. Sülsen
- Instituto
de Química y Metabolismo del Fármaco (IQUIMEFA), CONICET—Universidad de Buenos Aires, Junín 956 2°P, 1113 Buenos Aires, Argentina
- Cátedra
de Farmacognosia, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956 2°P, 1113 Buenos Aires, Argentina
- . Tel: 54-11-5287-4286. Fax: 54-11-4508-3642
| |
Collapse
|
3
|
Coro-Bermello J, López-Rodríguez ER, Alfonso-Ramos JE, Alonso D, Ojeda-Carralero GM, Prado GA, Moreno-Castillo E. Identification of novel thiadiazin derivatives as potentially selective inhibitors towards trypanothione reductase from Trypanosoma cruzi by molecular docking using the numerical index poses ratio Pr and the binding mode analysis. SN APPLIED SCIENCES 2021. [DOI: 10.1007/s42452-021-04375-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Abstract
Chagas disease is a serious health problem in Central and South America for which effective treatment is not currently available. This illness is caused by the protozoa Trypanosoma cruzi, a species that relies on a thiol-based metabolism to regulate oxidative stress. Trypanothione reductase enzyme plays a central role in the metabolic pathway of the parasite. In this work, a virtual screening of a library of novel thiadiazine derivatives against trypanothione reductase using molecular docking was performed. Four different series of hybrid ligands having in the structure one or two peptoid moieties (series I and II) or the tetrazole ring (series III and IV) were considered. An ad hoc numerical index called poses ratio was introduced to interpret the results of the docking analysis and to establish relevant structure-interaction relationships. In addition, six binding modes were found for the ligands with the highest populated conformational clusters after applying contact-based analysis. The most regular and relevant were binding modes I and II, found mainly for ligands from series I. A subsequent molecular docking on human glutathione reductase enzyme allowed to assess the possible cytotoxicity of the ligands towards human cells. A selective binding profile was found for ligands with interactions in the Hydrophobic cleft, the spermidine and the Z subsites inside the active site of trypanothione reductase. At the end of the study, new thiadiazine-based compounds were identified as plausible candidates to selectively inhibit the parasitic enzyme.
Graphic abstract
Collapse
|
4
|
Scotti MT, Monteiro AFM, de Oliveira Viana J, Bezerra Mendonça Junior FJ, Ishiki HM, Tchouboun EN, De Araújo RSA, Scotti L. Recent Theoretical Studies Concerning Important Tropical Infections. Curr Med Chem 2020; 27:795-834. [DOI: 10.2174/0929867326666190711121418] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2018] [Revised: 07/20/2018] [Accepted: 04/12/2019] [Indexed: 01/02/2023]
Abstract
Neglected Tropical Diseases (NTDs) form a group of diseases that are strongly associated
with poverty, flourish in impoverished environments, and thrive best in tropical areas,
where they tend to present overlap. They comprise several diseases, and the symptoms
vary dramatically from disease to disease, often causing from extreme pain, and untold misery
that anchors populations to poverty, permanent disability, and death. They affect more than 1
billion people worldwide; mostly in poor populations living in tropical and subtropical climates.
In this review, several complementary in silico approaches are presented; including
identification of new therapeutic targets, novel mechanisms of activity, high-throughput
screening of small-molecule libraries, as well as in silico quantitative structure-activity relationship
and recent molecular docking studies. Current and active research against Sleeping
Sickness, American trypanosomiasis, Leishmaniasis and Schistosomiasis infections will hopefully
lead to safer, more effective, less costly and more widely available treatments against
these parasitic forms of Neglected Tropical Diseases (NTDs) in the near future.
Collapse
Affiliation(s)
- Marcus Tullius Scotti
- Postgraduate Program in Natural and Synthetic Bioactive Products, Federal University of Paraíba, Joao Pessoa - PB, Brazil
| | - Alex France Messias Monteiro
- Postgraduate Program in Natural and Synthetic Bioactive Products, Federal University of Paraíba, Joao Pessoa - PB, Brazil
| | - Jéssika de Oliveira Viana
- Postgraduate Program in Natural and Synthetic Bioactive Products, Federal University of Paraíba, Joao Pessoa - PB, Brazil
| | | | - Hamilton M. Ishiki
- University of Western Sao Paulo (Unoeste), Presidente Prudente, SP, Brazil
| | | | - Rodrigo Santos A. De Araújo
- Laboratory of Synthesis and Drug Delivery, Department of Biological Science, State University of Paraiba, Joao Pessoa, PB, Brazil
| | - Luciana Scotti
- Postgraduate Program in Natural and Synthetic Bioactive Products, Federal University of Paraíba, Joao Pessoa - PB, Brazil
| |
Collapse
|
5
|
Ogungbe IV, Setzer WN. The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking Investigations. Molecules 2016; 21:E1389. [PMID: 27775577 PMCID: PMC6274513 DOI: 10.3390/molecules21101389] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Revised: 10/06/2016] [Accepted: 10/12/2016] [Indexed: 12/11/2022] Open
Abstract
Malaria, leishmaniasis, Chagas disease, and human African trypanosomiasis continue to cause considerable suffering and death in developing countries. Current treatment options for these parasitic protozoal diseases generally have severe side effects, may be ineffective or unavailable, and resistance is emerging. There is a constant need to discover new chemotherapeutic agents for these parasitic infections, and natural products continue to serve as a potential source. This review presents molecular docking studies of potential phytochemicals that target key protein targets in Leishmania spp., Trypanosoma spp., and Plasmodium spp.
Collapse
Affiliation(s)
- Ifedayo Victor Ogungbe
- Department of Chemistry and Biochemistry, Jackson State University, Jackson, MS 39217, USA.
| | - William N Setzer
- Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA.
| |
Collapse
|
6
|
Argüelles AJ, Cordell GA, Maruenda H. Molecular Docking and Binding Mode Analysis of Plant Alkaloids as in Vitro and in silico Inhibitors of Trypanothione Reductase from Trypanosoma cruzi. Nat Prod Commun 2016. [DOI: 10.1177/1934578x1601100118] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Trypanothione reductase (TryR) is a key enzyme in the metabolism of Trypanosoma cruzi, the parasite responsible for Chagas disease. The available repertoire of TryR inhibitors relies heavily on synthetic substrates of limited structural diversity, and less on plant-derived natural products. In this study, a molecular docking procedure using a Lamarckian Genetic Algorithm was implemented to examine the protein-ligand binding interactions of strong in vitro inhibitors for which no X-ray data is available. In addition, a small, skeletally diverse, set of natural alkaloids was assessed computationally against T. cruzi TryR in search of new scaffolds for lead development. The preferential binding mode (low number of clusters, high cluster population), together with the deduced binding interactions were used to discriminate among the virtual inhibitors. This study confirms the prior in vitro data and proposes quebrachamine, cephalotaxine, cryptolepine, (22 S,25 S)-tomatidine, (22 R,25 S)-solanidine, and (22 R,25 R)-solasodine as new alkaloid scaffold leads in the search for more potent and selective TryR inhibitors.
Collapse
Affiliation(s)
- Alonso J. Argüelles
- Pontificia Universidad Católica del Perú, Departamento de Ciencias - Sección Química, Lima, Perú
| | - Geoffrey A. Cordell
- Pontificia Universidad Católica del Perú, Departamento de Ciencias - Sección Química, Lima, Perú
- Natural Products Inc., Evanston, IL 60203, USA
- Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
| | - Helena Maruenda
- Pontificia Universidad Católica del Perú, Departamento de Ciencias - Sección Química, Lima, Perú
| |
Collapse
|